Literature DB >> 23899640

N-acetylcysteine augmentation to tranylcypromine in treatment-resistant major depression.

André F Carvalho, Danielle S Macêdo, Panagiota Goulia, Thomas N Hyphantis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23899640     DOI： 10.1097/JCP.0b013e31829839c6

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  6 in total

Review 1.  Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.

Authors:  Mark J Niciu; Dawn F Ionescu; Erica M Richards; Carlos A Zarate
Journal:  J Neural Transm (Vienna)       Date:  2013-12-08       Impact factor: 3.575

2.  N-Acetylcysteine for Nonsuicidal Self-Injurious Behavior in Adolescents: An Open-Label Pilot Study.

Authors:  Kathryn R Cullen; Bonnie Klimes-Dougan; Melinda Westlund Schreiner; Patricia Carstedt; Nicholas Marka; Katharine Nelson; Michael J Miller; Kristina Reigstad; Ana Westervelt; Meredith Gunlicks-Stoessel; Lynn E Eberly
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-10-20       Impact factor: 2.576

3.  New Somatic Treatments for Child and Adolescent Depression.

Authors:  Kathryn R Cullen; Laura E Padilla; Victoria N Papke; Bonnie Klimes-Dougan
Journal:  Curr Treat Options Psychiatry       Date:  2019-11-12

Review 4.  Oxidative Stress Implications in the Affective Disorders: Main Biomarkers, Animal Models Relevance, Genetic Perspectives, and Antioxidant Approaches.

Authors:  Ioana Miruna Balmus; Alin Ciobica; Iulia Antioch; Romeo Dobrin; Daniel Timofte
Journal:  Oxid Med Cell Longev       Date:  2016-08-01       Impact factor: 6.543

5.  Altered KYN/TRP, Gln/Glu, and Met/methionine sulfoxide ratios in the blood plasma of medication-free patients with major depressive disorder.

Authors:  Hidehiro Umehara; Shusuke Numata; Shin-Ya Watanabe; Yutaka Hatakeyama; Makoto Kinoshita; Yukiko Tomioka; Kiyoshi Nakahara; Takeshi Nikawa; Tetsuro Ohmori
Journal:  Sci Rep       Date:  2017-07-07       Impact factor: 4.379

Review 6.  Neuroimmune Mechanisms as Novel Treatment Targets for Substance Use Disorders and Associated Comorbidities.

Authors:  Mark D Namba; Jonna M Leyrer-Jackson; Erin K Nagy; M Foster Olive; Janet L Neisewander
Journal:  Front Neurosci       Date:  2021-04-15       Impact factor: 4.677
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.